

Open House Days 2024, Leuven

Moderator: Dr. Carsten Worsøe (Novo Nordisk)
Location: Brabantal, Brabantlaan 1 – 3001 Leuven

Time	Topic	Speaker
8.30	Registration	
9.00	Welcome	Eric Meyers /Piet Christiaens Nelson Labs
March 26 – Morning sessions		
9.15	How to Implement USP<665> requirements before 2026	Marine Lepoutre GSK
9.45	ELSIE Member Survey: The implementation of USP<665> within its member companies	Dr. Alicja Sobantka Octapharma - ELSIE Member Company
10.15	PANEL DISCUSSION on the implementation of USP <665>	-
10.45	BREAK	
11.15	USP <665> Focus on Component Qualification – What About Component Selection?	Dr. Simone Biel Senior Regulatory Consultant Merck Life Science KGaA, Darmstadt, Germany
11.45	Implementing X-Ray for Single Use Systems Sterilization: Current Status	Dr. Samuel Dorey Sartorius
12.15	Considerations for Validation of Filters used in (Bio)Pharmaceutical Manufacturing (title TBC)	Frederick LaPlant 3M
12.45	Lunch	
March 26 - Afternoon sessions		
13.45	Cytiva Approach for Extractables and Leachables Qualification and Risk Assessment of a Single-Use System: Case Studies	Patrick Evrard Cytiva
14.15	Extractables & Leachables from Single-Use Systems and Their Assessment in Advanced Therapy Medicinal Product (ATMP) production.	Dr. Armin Hauk Sartorius
14.45	BREAK	
15.00	The UCB approach to Qualification and Validation of Biopharmaceutical Manufacturing Equipment (Title TBC)	Isabelle Sbille UCB
15.30	Qualification of Single Use Materials for Biopharmaceutical Manufacturing	Aidan Sexton Johnson & Johnson
16.00	Leachable Risk Assessment Approaches: A Comparison of USP <665>, Biophorum, and other Methods for Assessing Leachable Risk in BioPharmaceutical Manufacturing Systems	Jason Creasey Maven E&L
16.30	Transfer to Nelson Labs facilities for a LAB TOUR – followed by RECEPTION	
19.30	End Day 1	

Open House Days 2024, Leuven

Moderator: Dr. Carsten Worsøe (Novo Nordisk)
Location: Brabantal, Brabantlaan 1 – 3001 Leuven

Time	Topic	Speaker
March 27 - Morning sessions		
8.30	Registration	
9.00	USP <665> and <1665>, Extractables for Components used in Pharmaceutical and Biopharmaceutical Manufacturing: Past, Present and Future(?).	Dr. Dennis Jenke, Principal Consultant Nelson Labs
9.45	Assisting Companies in the Qualification of Single-Use Materials: Overview of Different Steps to be Considered Beyond Analytical Chemistry Testing	Ir. Karen Pieters Nelson Labs
10.30	BREAK	
10.45	Extractables Testing of Bioprocessing Materials: From Conceptual Theory to Actionable Extractable Study Design – CASE STUDIES Showing the Practical Hurdles when Performing E-studies	Dr. Koen Smets Nelson Labs
11.15	Potential Designs for Leachable Studies on Biopharmaceutical Manufacturing Equipment	Dr. Pieter Van Wouwe Nelson Labs
11.45	Filter Integrity Testing of Sterilizing Grade Filters	Ir. Peter Cornelis Nelson Labs
12.15	Q&A	
12.30	Lunch	
March 27 - Afternoon sessions		
13.30	Viral Clearance Testing for Filters	Tonya Morris Nelson Labs
14.00	Good Identification Practices in Non-Targeted Screening Analyses: the Key-Information to link a Compound to its Structure and Relevant Toxicological Information	Dr. Ward d’Autry Nelson Labs
14.30	Toxicological Safety Assessment of Process Equipment-Related Leachables (PERLs) in the Context of USP<665>	Ir. Kevin Breesch Nelson Labs
15.00	BREAK	
15.15	Panel Discussion – Final Q&A Session	Participants to be announced
15.45	Final Thoughts & Comments	
16.00	CLOSE	